Consider the recent sell-off in Celsius Holdings (CELH) a buying opportunity, as its acquisition of Alani strengthens its market position. LifeMD (LFMD) is presented as an undervalued telehealth play, trading at a significant discount to its competitor Hims (HIMS). The recent price drop in CorMedix (CRMD) is seen as a market overreaction, creating an attractive entry point for its money-saving medical product, Defencaf. For a contrarian investment in real estate, The Real Brokerage (REAX) is rapidly gaining market share and is considered cheaply valued. These opportunities focus on high-growth companies and deep value situations that appear to be currently mispriced by the market.

LifeMD (LFMD)

• The speaker describes LifeMD as a "mini-Hims," viewing it as a smaller, undervalued version of its larger competitor, Hims & Hers Health (HIMS).
• The company's business is approximately 70% healthcare (LifeMD.com) and 30% a separate, slow-growing software business called WorkSimply.
• This software business is seen as a drag on the company's overall growth metrics. The speaker believes that if LifeMD sells WorkSimply, its revenue growth would look much more impressive and comparable to Hims.
• A key valuation metric mentioned is EV over GP over RG (Enterprise Value / Gross Profit / Revenue Growth). On this metric, LifeMD is currently trading at a valuation nearly four times cheaper than Hims.
• The speaker likes to buy LifeMD when it is "ignored" and trading at a significant discount to Hims. The recent price action, where Hims experienced a short squeeze while LifeMD did not, is seen as an opportunity.
• A potential headwind mentioned is that the company's strategy to get insurance to cover GLP-1 weight-loss drugs has not been successful so far.

Takeaways

• Bullish Sentiment: The primary investment thesis is that LifeMD is significantly undervalued compared to its direct competitor, Hims.
• Potential Catalyst: A future sale of the non-core WorkSimply software business could unlock significant value by revealing the true growth rate of the core healthcare business.
• Actionable Signal: The speaker considers LifeMD an attractive buy when it is more than three times cheaper than Hims based on their specific valuation formula.

CorMedix (CRMD)

• The company's main product is Defencaf, an anti-infection fluid used in hemodialysis catheters after treatment.
• The core appeal of Defencaf is that it saves money for Medicare and Medicaid by preventing costly infections and hospitalizations. This gives it a strong reason to be adopted by the healthcare system.
• At a price of around $250 per vial, it is not expensive enough to attract the negative attention that Medicare directs towards drugs costing tens of thousands of dollars.
• The stock is described as extremely cheap, trading "more than 10 times cheaper than what I would usually consider cheap."
• The stock price recently dropped after the company issued new shares to fund an acquisition. The speaker believes the market overreacted, viewing the acquisition as a positive move with good synergies.
• Future growth opportunities include:
  • Increased sales as the second-largest US dialysis provider, DaVita, ramps up its use of Defencaf.
  • Expanding the use of Defencaf to the TPN (Total Parenteral Nutrition) market, which involves feeding tubes and is considered a very large potential market.

Takeaways

• Strong Bullish Sentiment: The speaker is very positive on CorMedix due to its extremely low valuation, a product that saves the healthcare system money, and clear growth paths.
• Buying Opportunity: The recent stock price decline is viewed as a market misunderstanding, creating an attractive entry point for investors who believe in the company's fundamentals.
• Key Metrics to Watch: Investors should monitor revenue growth for Defencaf in the upcoming quarters (Q3/Q4) and look for any announcements regarding its expansion into the TPN market.

Celsius Holdings (CELH)

• The speaker views the recent sell-off in Celsius stock from its highs in the $80-$90 range as a buying opportunity.
• The company is considered fundamentally stronger now due to its recent acquisition of competitor Alani.
  • Alani is a popular energy drink with a 90% female customer base, which complements Celsius's gender-neutral branding.
  • This acquisition effectively gives Celsius control over both the gender-neutral and female-focused energy drink markets, removing a key competitor.
• The brand is seen as highly aligned with Gen Z consumers through its social media-friendly flavors, constantly changing options, and modern branding (e.g., "Peach Vibe").
• The business is described as recession-resistant because of its low price point ($1-$2 per can) and the addictive nature of its main ingredient, caffeine.
• International sales are beginning to accelerate, providing another significant avenue for growth.

Takeaways

• Bullish Sentiment: The investment thesis is based on strong brand momentum, strategic market consolidation through the Alani acquisition, and a long runway for growth.
• Valuation Context: While it is the most expensive stock of the four discussed (at an EV/GP/RG of 0.46), the premium is considered justified due to its dominant market position and location in the historically high-performing beverage sector.
• Growth Drivers: Future performance will likely be driven by continued market share gains against Monster (MNST), successful integration of Alani, and expansion into international markets.

The Real Brokerage (REAX)

• This company is the speaker's primary investment for the disruption of the traditional real estate brokerage model.
• The speaker is skeptical of the recent hype in Opendoor (OPEN) and prefers the fundamental story of REAX.
• REAX's competitive advantage is its agent-centric business model, which attracts top-performing agents by offering them a much higher commission split with a generous cap.
• This model has allowed REAX to achieve "stunning" growth in agent count, revenue, and transaction volume, even while the overall real estate market has been in a slump.
• The company is building a vertically integrated platform by expanding into mortgages, financing, and other services for its agents.
• The stock has been relatively flat for the past three years and is considered cheap, with an EV over GP over RG of 0.14.

Takeaways

• Bullish Sentiment: REAX is presented as a high-growth disruptor in a massive industry, available at a cheap valuation.
• Contrarian Play: The investment is positioned as a more fundamentally sound alternative to the more speculative, headline-driven moves in stocks like Opendoor.
• Potential Catalyst: A recovery in the broader real estate market could act as a major tailwind, amplifying the company's already strong organic growth. The key is its ability to continue attracting top agents and growing its market share.